Trexquant Investment’s Viridian Therapeutics VRDN Stock Holding History

Trexquant Investment’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-28,239	Closed	-$879K	–	2077
2025 Q4	$879K	Buy	+28,239	New	+$775K	0.01%	1220
2025 Q1	–	Sell	-120,065	Closed	-$2.3M	–	1900
2024 Q4	$2.3M	Sell	120,065 -22,576	-16%	-$491K	0.03%	810
2024 Q3	$3.25M	Buy	142,641 +100,817	+241%	+$1.65M	0.04%	640
2024 Q2	$544K	Buy	+41,824	New	+$579K	0.01%	1217
2023 Q1	–	Sell	-35,887	Closed	-$1.05M	–	1806
2022 Q4	$1.05M	Buy	+35,887	New	+$827K	0.03%	624
2018 Q4	–	Sell	-669	Closed	-$56K	–	1328
2018 Q3	$56K	Buy	+669	New	+$63.1K	﹤0.01%	909
2018 Q2	–	Sell	-1,050	Closed	-$110K	–	1251
2018 Q1	$110K	Sell	1,050 -13	-1%	-$1.41K	0.01%	1012
2017 Q4	$166K	Buy	+1,063	New	+$135K	0.02%	970

Other funds holding VRDN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Trexquant Investment's VRDN Position: Q1 2026 in Review

Trexquant Investment sold out of Viridian Therapeutics (VRDN) in Q1 2026, closing a stake of 28,239 shares — an estimated $879K sold.

Trexquant Investment first reported a position in VRDN in Q4 2017 and held it in 8 quarters. The position peaked at $3.25M in Q3 2024. 225 funds tracked by Wall St. Rank hold VRDN as of Q1 2026.

Trexquant Investment reported no remaining Viridian Therapeutics position as of Q1 2026 after selling out during the quarter.
Trexquant Investment sold 28,239 Viridian Therapeutics shares in Q1 2026, an estimated $879K.
Trexquant Investment first reported a position in Viridian Therapeutics in Q4 2017 and held it in 8 quarters.
Trexquant Investment's Viridian Therapeutics position peaked at $3.25M in Q3 2024.
225 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q1 2026.

Based on Trexquant Investment's 13F filing for Q1 2026, filed 15 May 2026.